The stocks of PFE have been given a price target of $43 by research analysts from Berenberg Bank in a Thursday report. The report was then sent out to most of the investors and clients of the company. The brokerage has also put up a rating of neutral on the stock of this biopharmaceutical company. The price target set by the company over the period suggests an increase of 8.50% over the previous close of the company.
The Stock Commentary Of PFE
There have been quite a few research equities that have commented on the stocks of PFE. Mizuho Securities has already reiterated a rating of neutral with a price target of $$2 in a 12th May research report. JPMorgan Chase & Co has also put up a price target of $40 along with a rating of neutral in a 24th May research report. SVB Leerink has also increased the price target of the company from $39 to $43 with a rating of market perform in a 5th May research report.
The Goldman Sachs Group has also set up a price target of $45 with a price rating of neutral in a 24th May research report. TheStreet has increased the rating of the company from c+ to b- in a 3rd May research report.
Twelve investment analysts have already given the stocks of the company a rating of hold, while two others have provided the company with a rating of buy. Currently, the stocks of PFE have a hold rating with a price target of $40.07.
The stocks of PFE traded on Tuesday at $39.63. The debt-to-equity ratio of the company over the period was 0.51, with a quick ratio of 1.61, and a 1.48 current ratio. The moving average price of the company over a period of 50-days is $38.91. The year low of the company is $31.61 with a year high set at $43.08. The market cap of the firm is $221.84 billion, with a 20.22 PE ratio, and a 1.43 PEG ratio.
